Global Rx-360 Consortium Aims To Curb Supply Chain Threats
This article was originally published in The Tan Sheet
Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008
You may also be interested in...
Manufacturers should expect that remote audits of suppliers may take longer than onsite ones until they get more familiar with these audits; it is also important to abide by data confidentiality rules and take frequent breaks when conducting these audits, says Rx-360 CEO.
FDA plans to hold a public workshop this spring to begin the task of combating profit-motivated adulteration of regulated products
BEIJING - As FDA leaders select inspectors to deploy across three offices being set up in China, the agency is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drug manufacturers that export to the U.S